EBMT 2024 | Key advancements in the treatment of BPDCN from EBMT 2024
Cristina Papayannidis
• 22 Apr 2024
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses recent advancements in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). She mentions ongoing clinical trials investigating tagraxofusp in combination with hypomethylating agents or venetoclax, as well as anti-CD123 CAR T-cells and CAR-NK cells. However, BPDCN is a rare disease, prolonging the clinical trial timeline. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Menarini Stemline: Honoraria.
